BRIEF — iBio — IBIO — 610 Plus Semaglutide Preserves Lean Mass In Eight — Week Obese NHP Study

Oct 13 (Reuters) — iBio Inc: Ibio - Ibio-610 Plus Semaglutide Preserves Lean Mass In Eight-week Obese Nhp Study Ibio - Ibio-610 Demonstrates 97% Reduction In Active Activin E At Week 8 In Nhp Study Ibio - Expects To Start First-in-human Trials Of Ibio-610 In First Half Of 2027 Ibio - Fat Accounted For 93% Of Weight Lost With Ibio-610 Plus Semaglutide At Week 8 Source text:... Further company coverage: IBIO.O (Reuters.Briefs@thomsonreuters.com;)